JP6404358B2 - マルトール第二鉄の結晶形態 - Google Patents

マルトール第二鉄の結晶形態 Download PDF

Info

Publication number
JP6404358B2
JP6404358B2 JP2016551318A JP2016551318A JP6404358B2 JP 6404358 B2 JP6404358 B2 JP 6404358B2 JP 2016551318 A JP2016551318 A JP 2016551318A JP 2016551318 A JP2016551318 A JP 2016551318A JP 6404358 B2 JP6404358 B2 JP 6404358B2
Authority
JP
Japan
Prior art keywords
polymorph
degrees
type
maltol
polymorphs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016551318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535510A5 (enExample
JP2017535510A (ja
Inventor
デイヴィット・ポール・チャイルズ
Original Assignee
シールド ティーエックス （ユーケー） リミテッド
シールド ティーエックス （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6404358(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by シールド ティーエックス （ユーケー） リミテッド, シールド ティーエックス （ユーケー） リミテッド filed Critical シールド ティーエックス （ユーケー） リミテッド
Publication of JP2017535510A publication Critical patent/JP2017535510A/ja
Publication of JP2017535510A5 publication Critical patent/JP2017535510A5/ja
Application granted granted Critical
Publication of JP6404358B2 publication Critical patent/JP6404358B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds
    • C07F15/025—Iron compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
JP2016551318A 2014-10-28 2015-10-23 マルトール第二鉄の結晶形態 Active JP6404358B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1419174.6 2014-10-28
GB1419174.6A GB2531742B (en) 2014-10-28 2014-10-28 Polymorphs of ferric maltol
PCT/EP2015/074653 WO2016066555A1 (en) 2014-10-28 2015-10-23 Crystalline forms of ferric maltol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018169541A Division JP6678711B2 (ja) 2014-10-28 2018-09-11 マルトール第二鉄の結晶形態

Publications (3)

Publication Number Publication Date
JP2017535510A JP2017535510A (ja) 2017-11-30
JP2017535510A5 JP2017535510A5 (enExample) 2018-04-05
JP6404358B2 true JP6404358B2 (ja) 2018-10-10

Family

ID=52103522

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016551318A Active JP6404358B2 (ja) 2014-10-28 2015-10-23 マルトール第二鉄の結晶形態
JP2018169541A Active JP6678711B2 (ja) 2014-10-28 2018-09-11 マルトール第二鉄の結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018169541A Active JP6678711B2 (ja) 2014-10-28 2018-09-11 マルトール第二鉄の結晶形態

Country Status (18)

Country Link
US (1) US9802973B2 (enExample)
EP (1) EP3160951B1 (enExample)
JP (2) JP6404358B2 (enExample)
KR (1) KR102576930B1 (enExample)
CN (1) CN107001310B (enExample)
AU (1) AU2015340825B2 (enExample)
CA (1) CA2944210C (enExample)
CL (1) CL2017001030A1 (enExample)
EA (1) EA033323B1 (enExample)
ES (1) ES2661944T3 (enExample)
GB (1) GB2531742B (enExample)
IL (1) IL251863A0 (enExample)
MX (1) MX370730B (enExample)
PL (1) PL3160951T3 (enExample)
SA (1) SA517381406B1 (enExample)
SG (1) SG11201702639RA (enExample)
WO (1) WO2016066555A1 (enExample)
ZA (1) ZA201702136B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol
CN112574158B (zh) * 2020-12-29 2022-08-02 南京百泽医药科技有限公司 一种麦芽酚铁晶型ii及其制备方法
IT202100018578A1 (it) 2021-07-14 2023-01-14 Indena Spa Dispersione amorfa di maltolo ferrico e relativo processo di preparazione
AU2022349859A1 (en) * 2021-09-21 2024-05-02 Apicore Pharmaceuticals Private Limited An improved process for the preparation of ferric maltol
CN119638662B (zh) * 2024-12-09 2025-11-14 金陵药业股份有限公司 一种麦芽酚铁-草酸共晶及其制备方法
CN119638661B (zh) * 2024-12-09 2025-11-14 金陵药业股份有限公司 一种麦芽酚铁-槲皮素共晶及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE37534E1 (en) 1982-10-22 2002-01-29 Btg International Limited Pharmaceutical compositions
EP0107458B1 (en) 1982-10-22 1987-07-29 National Research Development Corporation Pharmaceutical compositions
GB8410290D0 (en) * 1984-04-19 1984-05-31 Callingham B A Pharmaceutical compositions
GB0211500D0 (en) * 2002-05-18 2002-06-26 Vitra Pharmaceuticals Ltd Method of forming iron hydroxypyrone compounds
GB201101370D0 (en) * 2011-01-27 2011-03-09 Iron Therapeutics Holdings Ag Process
WO2014165607A2 (en) * 2013-04-02 2014-10-09 Stealth Peptides International, Inc. Aromatic-cationic peptide formulations, compositions and methods of use
GB2531742B (en) 2014-10-28 2016-10-05 Iron Therapeutics Holdings Ag Polymorphs of ferric maltol

Also Published As

Publication number Publication date
CL2017001030A1 (es) 2018-01-19
EP3160951B1 (en) 2017-12-06
KR102576930B1 (ko) 2023-09-12
AU2015340825B2 (en) 2016-11-24
IL251863A0 (en) 2017-06-29
KR20170071446A (ko) 2017-06-23
GB201419174D0 (en) 2014-12-10
SA517381406B1 (ar) 2021-03-15
CA2944210A1 (en) 2016-05-06
CN107001310A (zh) 2017-08-01
CA2944210C (en) 2017-06-20
ZA201702136B (en) 2018-11-28
WO2016066555A1 (en) 2016-05-06
US9802973B2 (en) 2017-10-31
CN107001310B (zh) 2020-05-22
JP2018197268A (ja) 2018-12-13
BR112017008903A2 (pt) 2017-12-19
JP6678711B2 (ja) 2020-04-08
EA201790667A1 (ru) 2017-08-31
PL3160951T3 (pl) 2018-07-31
JP2017535510A (ja) 2017-11-30
GB2531742A (en) 2016-05-04
ES2661944T3 (es) 2018-04-04
AU2015340825A1 (en) 2016-08-25
MX370730B (es) 2019-12-20
MX2017005413A (es) 2017-10-04
EA033323B1 (ru) 2019-09-30
EP3160951A1 (en) 2017-05-03
GB2531742B (en) 2016-10-05
US20170260222A1 (en) 2017-09-14
SG11201702639RA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
JP6678711B2 (ja) マルトール第二鉄の結晶形態
JP6206689B2 (ja) ５−アミノ−２，３−ジヒドロフタラジン−１，４−ジオンナトリウム塩の結晶形ｉまたはｉｉを含有する医薬製剤
JP2020183408A (ja) ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
JP2009537603A (ja) ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形
TW201043623A (en) Crystalline tripeptide epoxy ketone protease inhibitors
JP6779972B2 (ja) 呼吸器合胞体ウイルス（ｒｓｖ）感染症の処置のためのｎ−［（３−アミノ−３−オキセタニル）メチル］−２−（２，３−ジヒドロ−１，１−ジオキシド−１，４−ベンゾチアゼピン−４（５ｈ）−イル）−６−メチル−４−キナゾリンアミンの結晶形
WO2015109445A1 (zh) 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
CN105189513A (zh) 葡萄糖醇，1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
WO2016155578A1 (zh) 达格列净的新晶型及其制备方法
EP0703915B1 (en) Xamoneline tartrate
JP2004526714A (ja) ラモトリジンの新しい結晶形およびそれらの調製方法
CN117088925B (zh) 一种化合物晶型及其制备、组合物和用途
JP5836360B2 (ja) １‐シクロプロピル‐８‐メチル‐７‐［５‐メチル‐６‐（メチルアミノ）‐３‐ピリジニル］‐４‐オキソ‐１，４‐ジヒドロ‐３‐キノリンカルボン酸塩
WO2016195021A1 (ja) 水性液剤
KR100912214B1 (ko) 세프디니르 세슘 염의 결정형
HK1233619A1 (en) Crystalline forms of ferric maltol
HK1233619B (en) Crystalline forms of ferric maltol
JP2008504369A (ja) １，２４（ｓ）−ジヒドロキシビタミンｄ２の結晶形態
BR112017008903B1 (pt) Formas cristalinas de maltol férrico
HK1223929B (zh) 5-氨基-2，3-二氢-(2，3-二氮杂萘)-1，4-二酮钠盐的晶型
NZ719970B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180208

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180208

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180912

R150 Certificate of patent or registration of utility model

Ref document number: 6404358

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250